Fucich L F, Freeman S M, Marrogi A J
Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Biotech Histochem. 1996 Nov;71(6):298-303. doi: 10.3109/10520299609117179.
Monoclonal Antibody (MoAb) HNK, or anti-leu-7, is reactive with several neuroendocrine and nonneuroendocrine tumors. The aim of this study is to examine anti-leu-7 reactivity in thyroid neoplasms and its relationship to cellular proliferation as determined by anti-PCNA reactivity. The expression of anti-leu-7 in 56 thyroid neoplasms (24 papillary carcinomas, 14 follicular carcinomas, two medullary carcinomas and 16 follicular adenomas) was examined immunohistochemically. Papillary and follicular thyroid carcinomas reacted with anti-leu-7 in a membranous and cytoplasmic pattern in 88% and 93% of cases, respectively. The adjacent benign tissues were nonreactive. Only eight cases diagnosed as follicular adenomas were reactive with anti-leu-7. Furthermore, the mean proliferative index (PI), as measured by the percentage of nuclei immunoreactive with anti-PCNA, was greater than 30% in all thyroid neoplasms reactive with anti-leu-7. The PI was 58% for papillary carcinomas and 68% and 48% for follicular carcinomas, and follicular adenomas, respectively. Lesions originally classified as follicular adenomas that were nonreactive with anti-leu-7 had a PI of 24% and were reclassified as hyperplastic nodules. These data suggest that anti-leu-7 may be useful for characterizing thyroid neoplasia.
单克隆抗体（MoAb）HNK，即抗-Leu-7，可与多种神经内分泌和非神经内分泌肿瘤发生反应。本研究的目的是检测抗-Leu-7在甲状腺肿瘤中的反应性及其与通过抗增殖细胞核抗原（PCNA）反应性所确定的细胞增殖的关系。采用免疫组织化学方法检测了56例甲状腺肿瘤（24例乳头状癌、14例滤泡状癌、2例髓样癌和16例滤泡性腺瘤）中抗-Leu-7的表达。甲状腺乳头状癌和滤泡状癌分别有88%和93%的病例以膜性和胞质模式与抗-Leu-7发生反应。相邻的良性组织无反应。仅8例诊断为滤泡性腺瘤的病例与抗-Leu-7发生反应。此外，在所有与抗-Leu-7发生反应的甲状腺肿瘤中，以抗PCNA免疫反应阳性细胞核百分比衡量的平均增殖指数（PI）均大于30%。乳头状癌的PI为58%，滤泡状癌和滤泡性腺瘤的PI分别为68%和48%。最初分类为滤泡性腺瘤且与抗-Leu-7无反应的病变，其PI为24%，并重新分类为增生性结节。这些数据表明，抗-Leu-7可能有助于甲状腺肿瘤的特征性诊断。
